BTIG raised the firm’s price target on MDxHealth (MDXH) to $7 from $6 and keeps a Buy rating on the shares. The company drove a big uplift in its liquid-based test volumes in Q3 in part due to strength from its Resolve test and new contribution from its recently acquired ExoDx test, which the company recently acquired from Bio-Techne, the analyst tells investors in a research note. MDxHealth’s reported Q3 was also highlighted by robust volume growth, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- Positive Outlook for MDxHealth: Strategic Moves and Undervalued Growth Potential Reinforce Buy Rating
- Mdxhealth S.A. Reports Strong Q3 Growth and Strategic Acquisition
- Positive Outlook for MDxHealth: Strategic Acquisition and Focus on High-Return Products Drive Growth Potential
- Mdxhealth Reports Strong Q3 Growth and Strategic Acquisition
- MDxHealth sees FY25 revenue $108M-$110M, consensus $94.05M